Which of the following conditions can present with cotton wool spots?
A 5-year-old boy presents with leucocoria in the right eye, diagnosed as diffuse retinoblastoma involving the entire globe. Examination of the left eye reveals a small 2-3 mm tumor in the periphery. What is the ideal management for this patient?
Which of the following is beneficial for a patient suffering from gyrate atrophy of the choroid due to deficiency of the enzyme Ornithine transcarbamylase?
Amsler's grid is used in:
Which of the following is NOT a presentation of retinoblastoma?
Which is the best investigation for diagnosing Best disease?
In vitreous base detachment, the vitreous body is detached from its attachment with which of the following structures?
A young patient presents with significant loss of central vision and a normal ERG. There is no obvious family history of similar presentation. What is the most likely diagnosis?
What is the objective of the ETDRS study?
A 25-year-old executive presents with metamorphopsia in his right eye. Fundus examination shows a shallow detachment at the macula. Fluorescein angiography reveals a 'smoke stack' sign. Which of the following management should be given?
Explanation: **Explanation:** **Cotton wool spots (CWS)**, also known as soft exudates, are not actually exudates. They represent areas of **focal retinal ischemia** in the nerve fiber layer (NFL). When precapillary arterioles are occluded, axoplasmic flow within the ganglion cell axons is interrupted, leading to the accumulation of organelles and debris. This manifests clinically as fuzzy, white, "fluffy" patches on the retina. **Why "All of the Above" is Correct:** Cotton wool spots are a non-specific sign of retinal hypoxia and can be seen in various systemic and local conditions: * **Diabetic Retinopathy (DR):** CWS are a hallmark of Pre-Proliferative Diabetic Retinopathy (PPDR). Their presence indicates significant retinal ischemia. * **Hypertensive Retinopathy:** They occur in Grade III (Modified Scheie Classification) or "Accelerated/Malignant" hypertension due to acute arteriolar constriction and subsequent ischemia. * **AIDS:** HIV microangiopathy is the most common clinical finding in the fundus of AIDS patients, and CWS are its most frequent manifestation (even in the absence of opportunistic infections like CMV retinitis). **High-Yield Clinical Pearls for NEET-PG:** 1. **Histology:** On microscopic examination, CWS correspond to **Cytoid bodies** (swollen axonal ends) in the nerve fiber layer. 2. **Differential Diagnosis (Mnemonic: "D-H-A-N-I"):** **D**iabetes, **H**ypertension, **A**IDS/Anemia, **N**eoplasia (Leukemia), **I**schemia (Retinal vein occlusions). 3. **Purtscher’s Retinopathy:** Characterized by multiple CWS and hemorrhages following severe head or chest trauma. 4. **Key Distinction:** Unlike hard exudates (which are lipid deposits from chronic leakage), CWS have blurred margins and usually resolve within 4–6 weeks as the debris is cleared.
Explanation: ### Explanation The management of Retinoblastoma (RB) is tailored to the stage of the disease in each eye, aiming primarily to save life, then the globe, and finally vision. **1. Why Option C is Correct:** * **Right Eye (RE):** The patient has diffuse involvement of the entire globe (Group E). In advanced unilateral or bilateral cases where there is no hope for vision and a high risk of extraocular spread, **Enucleation** is the gold standard. * **Left Eye (LE):** The tumor is small (2-3 mm) and peripheral. Small tumors (typically <3 mm in diameter and <2 mm in thickness) located away from the fovea and disc are ideal candidates for **Focal Therapy** (such as cryotherapy, laser photocoagulation, or Transpupillary Thermotherapy/TTT). This approach preserves vision and avoids the systemic side effects of chemotherapy. **2. Why Other Options are Wrong:** * **Option A:** Enucleation of both eyes is avoided whenever possible to prevent total blindness. If one eye has a treatable lesion, conservative management is preferred. * **Option B:** Observation is never an option for active retinoblastoma; it is a malignant tumor that will progress and metastasize if left untreated. * **Option D:** While Chemoreduction (VEC protocol) is used to shrink large tumors to make them amenable to focal therapy, it is not the primary choice for a globe already destroyed by diffuse disease (RE) or for a very small lesion that can be cured with focal therapy alone (LE). **Clinical Pearls for NEET-PG:** * **Most common intraocular malignancy** in children. * **Leucocoria** (white pupillary reflex) is the most common presentation. * **Flexner-Wintersteiner rosettes** are pathognomonic histological features. * **Calcification** on CT scan is a hallmark diagnostic sign. * **Genetic Basis:** Mutation in the *RB1* gene on chromosome **13q14**. Bilateral cases are always germline mutations.
Explanation: **Explanation:** **Gyrate Atrophy** is a rare, autosomal recessive chorioretinal degeneration caused by a deficiency of the mitochondrial enzyme **Ornithine Aminotransferase (OAT)**. This deficiency leads to a massive accumulation of ornithine in the blood and tissues (hyperornithinemia), which is toxic to the retinal pigment epithelium (RPE) and choroid. 1. **Why Option B is Correct:** Ornithine is a metabolic byproduct of the amino acid **Arginine**. Since the body cannot properly metabolize ornithine due to the enzyme defect, the primary treatment strategy is to reduce its production. An **Arginine-restricted diet** is the mainstay of management to lower systemic ornithine levels and slow the progression of chorioretinal atrophy. 2. **Why other options are wrong:** * **Option A:** While the goal is to lower ornithine, the diet must be **Arginine-free**, as arginine is the precursor. * **Option C:** While **Pyridoxine (Vitamin B6)** is a cofactor for the OAT enzyme and is beneficial in a small subset of "B6-responsive" patients, Folic acid has no established role in treating this specific condition. * **Option D:** **Angioid streaks** are associated with conditions like Pseudoxanthoma elasticum (PXE), Paget’s disease, and Sickle cell anemia (Mnemonic: **PEPSI**), but not with Gyrate atrophy. **High-Yield Clinical Pearls for NEET-PG:** * **Classic Triad:** Night blindness (Nyctalopia), constricted visual fields, and characteristic **scalloped (garland-shaped) chorioretinal atrophy** starting in the mid-periphery. * **Biochemical Hallmark:** Hyperornithinemia. * **Associated Findings:** High myopia, posterior subcapsular cataract, and cystoid macular edema (CME). * **Inheritance:** Autosomal Recessive.
Explanation: **Explanation:** **Amsler’s Grid** is a high-yield clinical tool used primarily to monitor and detect disorders of the **macula** (the central retina). It consists of a grid of horizontal and vertical lines with a central fixation point. **Why Maculopathy is correct:** The macula is responsible for central, high-resolution vision. In conditions like **Age-related Macular Degeneration (ARMD)** or **Central Serous Chorioretinopathy (CSCR)**, fluid or abnormal deposits (drusen) distort the retinal architecture. When a patient with maculopathy views the grid, they experience **metamorphopsia** (straight lines appearing wavy) or **scotomas** (missing areas/blind spots). It is the gold standard for home monitoring of "wet" ARMD. **Why other options are incorrect:** * **A. Colour vision:** Tested using **Ishihara plates**, Hardy-Rand-Rittler (HRR) charts, or the Farnsworth-Munsell 100-hue test. * **B. Retinal function test:** While Amsler’s grid tests a *part* of retinal function, this is too broad. Specific retinal function tests include **ERG** (Electroretinogram) for global retinal response or **EOG** (Electro-oculogram) for RPE function. * **D. Refractive errors:** Diagnosed via **Retinoscopy** or automated refractometers and corrected with lenses. **Clinical Pearls for NEET-PG:** * **Testing Distance:** The grid is held at a normal reading distance (**30 cm**) with near-vision correction on. * **Monocular Testing:** It must be performed **one eye at a time** to prevent the healthy eye from compensating for the diseased one. * **Metamorphopsia:** This is the earliest clinical sign of macular dysfunction detectable by the patient. * **Field Coverage:** Amsler’s grid evaluates the central **10° to 20°** of the visual field.
Explanation: **Explanation:** Retinoblastoma (RB) is the most common primary intraocular malignancy of childhood. The correct answer is **Cataract**, as it is typically **not** a primary presentation of retinoblastoma. In fact, the presence of a clear lens is a classic clinical feature used to differentiate RB from other causes of "white eye" (leucocoria), such as Congenital Cataract or Persistent Hyperplastic Primary Vitreous (PHPV). **Analysis of Options:** * **Leucocoria (A):** This is the **most common** presentation (60%). It is a "white pupillary reflex" caused by the light reflecting off the creamy-white tumor mass in the vitreous. * **Squint/Strabismus (B):** This is the **second most common** presentation (20%). It occurs when the tumor involves the macula, leading to loss of central vision and subsequent sensory deviation of the eye. While usually non-accommodative, any squint in a child warrants a fundus exam to rule out RB. * **Glaucoma (D):** Secondary glaucoma is a known late-stage presentation. It can occur due to anterior displacement of the iris-lens diaphragm by a large endophytic tumor or via neovascularization of the iris (Rubeosis Iridis). **Clinical Pearls for NEET-PG:** * **Genetics:** Mutation in the **RB1 gene** on chromosome **13q14**. * **Pathology:** Look for **Flexner-Wintersteiner rosettes** (highly specific) and Homer-Wright rosettes. * **Calcification:** Dystrophic calcification is a hallmark of RB; it is easily detected on **B-scan USG** or **CT scan** (appearing as "high-density" spots). * **Management:** The primary goal is life-saving, followed by globe and vision preservation. Intra-arterial chemotherapy (IAC) is a modern gold-standard for advanced cases.
Explanation: **Explanation:** **Best Disease (Vitelliform Macular Dystrophy)** is an autosomal dominant condition caused by a mutation in the **BEST1 gene**, which encodes the protein bestrophin-1. This protein is located in the **Retinal Pigment Epithelium (RPE)** and functions as a chloride channel. **Why Electrooculogram (EOG) is the correct answer:** The EOG measures the standing potential between the front and back of the eye, which reflects the metabolic health of the **RPE**. In Best disease, the RPE is diffusely dysfunctional. The hallmark diagnostic finding is an **abnormal EOG** with a **decreased Arden Index (<1.5)**. Crucially, the EOG is abnormal even in the pre-vitelliform stage and in asymptomatic carriers with a normal fundus, making it the "gold standard" for diagnosis. **Why other options are incorrect:** * **EEG (Electroencephalogram):** Measures electrical activity in the brain; used for epilepsy or sleep disorders, not ocular pathology. * **Electroneurogram:** Measures the conduction velocity of peripheral nerves; irrelevant to retinal diseases. * **Electroretinogram (ERG):** Measures the electrical response of the photoreceptors and inner retinal layers. In Best disease, the **ERG is typically normal** because the primary defect is in the RPE, not the neurosensory retina. **High-Yield Clinical Pearls for NEET-PG:** * **Fundus Appearance:** Classically described as an **"egg-yolk"** (vitelliform) lesion at the macula. * **Stages:** Pre-vitelliform → Vitelliform → Scrambled egg (vitelliruptive) → Atrophic. * **Arden Index:** Calculated as (Light peak / Dark trough). Normal is >2.0; **<1.5 is diagnostic for Best disease.** * **Inheritance:** Autosomal Dominant (Chromosome 11). * **Vision:** Surprisingly remains good for many years despite the dramatic appearance of the macular lesion.
Explanation: **Explanation:** The vitreous body is a transparent, gel-like substance that fills the posterior segment of the eye. It is not uniformly attached to the retina; rather, it has specific sites of firm adherence. **1. Why Ora-serrata is correct:** The **vitreous base** is the strongest and most permanent attachment of the vitreous. It is a 3–4 mm wide zone that straddles the **ora serrata** (extending approximately 2 mm anterior and 2 mm posterior to it). In a vitreous base detachment, the vitreous body pulls away from this specific anatomical landmark. Because this attachment is so strong, a true detachment here is rare and usually associated with severe blunt trauma, often resulting in a retinal dialysis. **2. Analysis of Incorrect Options:** * **A. Optic disc:** The attachment here is known as the **Weiss ring** (or Martegiani’s ring). While this is a site of firm attachment, its separation is characteristic of a standard Posterior Vitreous Detachment (PVD), not a vitreous base detachment. * **C. Posterior surface of the lens:** The vitreous is attached here via the **hyaloideo-capsular ligament (of Wieger)**. This is a circular attachment but is not the "vitreous base." * **D. Fovea centralis:** There is a firm attachment around the fovea, which is clinically significant in the pathogenesis of macular holes and vitreomacular traction syndrome, but it does not constitute the vitreous base. **Clinical Pearls for NEET-PG:** * **Hierarchy of Vitreous Attachment Strength:** Vitreous base (Strongest) > Optic Disc > Fovea > Along retinal vessels (Weakest). * **Retinal Dialysis:** This is a linear tear at the ora serrata, frequently caused by traumatic vitreous base avulsion. * **Shafer’s Sign:** The presence of "tobacco dust" (RPE cells) in the anterior vitreous following a tear/detachment; a high-yield clinical sign for retinal breaks.
Explanation: **Explanation:** **Stargardt’s Disease** is the most common hereditary macular dystrophy. It typically presents in the first or second decade of life with progressive, bilateral, symmetrical loss of central vision. 1. **Why it is correct:** The hallmark of Stargardt’s is the **discrepancy between the significant loss of central vision and a normal Electroretinogram (ERG)** in the early stages. This occurs because the ERG measures the global response of the retina; since Stargardt’s primarily affects the macula (a small area), the overall retinal function remains preserved initially. An **Electro-oculogram (EOG)** is also typically normal. 2. **Why the others are wrong:** * **Best’s Disease:** While it affects central vision, it is characterized by a **normal ERG but a highly abnormal EOG** (Arden index <1.5). It also typically shows a "fried-egg" vitelliform lesion. * **Retinitis Pigmentosa:** This primarily affects peripheral vision (tunnel vision) and night blindness. The **ERG is characteristically extinguished** or markedly reduced early on. * **Cone-Rod Dystrophy:** This involves early loss of central vision, but unlike Stargardt’s, the **Photopic ERG is significantly abnormal** from the start as it reflects generalized cone dysfunction. **High-Yield Clinical Pearls for NEET-PG:** * **Genetics:** Most commonly Autosomal Recessive (ABCA4 gene mutation). * **Fundus Appearance:** "Pisciform" (fish-flesh) flecks and a "beaten bronze" macula. * **FFA Finding:** **"Dark Choroid"** (Silent Choroid) due to the accumulation of lipofuscin which masks underlying choroidal fluorescence—a classic exam favorite. * **OCT:** Shows atrophy of the outer retinal layers and RPE in the foveal region.
Explanation: The **Early Treatment Diabetic Retinopathy Study (ETDRS)** is a landmark clinical trial in ophthalmology that established the current standards for managing diabetic retinopathy (DR). ### **Why Option A is Correct** One of the primary objectives of the ETDRS was to determine whether **650 mg of aspirin** daily could retard the progression of diabetic retinopathy or reduce the risk of vitreous hemorrhage. The study concluded that **aspirin does not affect the progression of DR**, nor does it increase the risk of retinal or vitreous hemorrhage. This is a high-yield fact because it confirms that diabetic patients can safely take aspirin for cardiovascular protection without ocular contraindications. ### **Analysis of Incorrect Options** * **Option B:** While the ETDRS did follow patients with various stages of DR, its primary focus was on the **timing of intervention** (early vs. deferred photocoagulation) rather than just observing visual outcomes over a fixed 2-year period. * **Option C:** This objective was primarily addressed by the **DRS (Diabetic Retinopathy Study)**, which proved that pan-retinal photocoagulation (PRP) reduces severe visual loss in Proliferative Diabetic Retinopathy (PDR). The ETDRS focused more on the timing of PRP and the benefit of focal laser for Macular Edema. ### **High-Yield Clinical Pearls for NEET-PG** * **Definition of CSME:** The ETDRS defined **Clinically Significant Macular Edema (CSME)** and established that focal/grid laser photocoagulation reduces the risk of moderate visual loss by 50%. * **Timing of PRP:** ETDRS recommended that PRP should be considered as eyes approach **High-Risk PDR** but is generally not indicated for mild to moderate Non-Proliferative Diabetic Retinopathy (NPDR). * **Classification:** The ETDRS classification of DR (based on the "Rule of 4-2-1") remains the gold standard for grading severity.
Explanation: ### Explanation The clinical presentation of a young adult male (executive/stressed professional) with **metamorphopsia** (distorted vision), a **shallow macular detachment**, and the classic **'smoke stack' appearance** on Fluorescein Angiography (FA) is diagnostic of **Central Serous Chorioretinopathy (CSCR)**. **1. Why Observation is the Correct Management:** CSCR is typically a self-limiting condition. Approximately **80–90% of cases undergo spontaneous resolution** within 3 to 4 months without any active intervention. Therefore, the standard initial management is observation and lifestyle modification (stress reduction, discontinuing steroids). **2. Why Other Options are Incorrect:** * **Options B & C (Systemic/Pulse Corticosteroids):** These are **contraindicated**. Steroids (topical, systemic, or inhaled) are a known major risk factor for the development and exacerbation of CSCR. Administering steroids can worsen the detachment or lead to chronicity. * **Option A (Topical Antibiotic-Steroid):** There is no infectious component in CSCR, and the steroid component would be detrimental. **3. Clinical Pearls for NEET-PG:** * **Demographics:** Most common in young to middle-aged males with **Type A personalities**. * **FA Findings:** * **Ink-blot appearance** (most common). * **Smoke-stack appearance** (due to convection currents in the subretinal fluid). * **Optical Coherence Tomography (OCT):** Shows a characteristic "double-layer sign" or neurosensory detachment with increased choroidal thickness (**Pachychoroid**). * **Indications for Laser/PDT:** If the condition persists beyond 4 months, recurs frequently, or is required for occupational reasons (e.g., pilots), **Argon Laser Photocoagulation** (to the leak) or **Photodynamic Therapy (PDT)** is considered.
Retinal Anatomy and Physiology
Practice Questions
Age-Related Macular Degeneration
Practice Questions
Diabetic Retinopathy
Practice Questions
Retinal Vascular Diseases
Practice Questions
Retinal Detachment
Practice Questions
Hereditary Retinal Dystrophies
Practice Questions
Inflammatory Retinal Diseases
Practice Questions
Retinal Tumors
Practice Questions
Retinopathy of Prematurity
Practice Questions
Retinal Imaging Techniques
Practice Questions
Intravitreal Pharmacotherapy
Practice Questions
Vitreoretinal Surgery
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free